AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18341671 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine 10 mg b.i.d. for 4.5 days
Number of subjects: 20
Study 18341671 — intervention group
Group type: COMPARATOR
Intervention: placebo for 4.5 days
Number of subjects: 20
Study 18341671 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 20
Study 18341671 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 15036788 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (80 mg)
Number of subjects: 8
Study 15036788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11879270 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal, multidisciplinary intervention involving rural healthcare providers and their healthcare system.
Number of subjects: 0
Study 11879270 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline data from the study.
Number of subjects: 0
Study 9773769 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation-based stress reduction intervention (audiotaped instructions during light treatments)
Number of subjects: 37
Study 9773769 — intervention group
Group type: COMPARATOR
Intervention: Control condition (light treatments alone with no taped instructions)
Number of subjects: 37
Study 7522629 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) at doses of 10, 50, 100, 250, or 500 mg/m2
Number of subjects: 15
Study 7522629 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric anti-CD20 monoclonal antibody (IDEC-C2B8)
Number of subjects: 15
Study 3122666 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT 375 mg/m2/day + MMC 5 mg/m2 for 1‐2 weeks
Number of subjects: 104
Study 3122666 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT + ACNU 60 mg/m2/week for 2 weeks (with a 4-week interval)
Number of subjects: 104
Study 31356262 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Number of subjects: 148
Study 31356262 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 148
Study 29438654 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive 6-day fungal culture
Number of subjects: 0
Study 29438654 — intervention group
Group type: COMPARATOR
Intervention: Negative 6-day fungal culture
Number of subjects: 0
Study 28444509 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention aimed at increasing adenoma detection rate (ADR)
Number of subjects: 263
Study 28444509 — intervention group
Group type: COMPARATOR
Intervention: Untrained group (control)
Number of subjects: 263
Study 28444509 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained group (intervention)
Number of subjects: 263
Study 28444509 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 263
Study 26289955 — intervention group
Group type: EXPERIMENTAL
Intervention: Stride Management Assist (SMA®) System
Number of subjects: 50
Study 26289955 — intervention group
Group type: COMPARATOR
Intervention: Functional Task Specific Training (FTST)
Number of subjects: 50
Study 24570980 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 × 5 mm dental implants with a novel nanostructured calcium-incorporated titanium surface
Number of subjects: 80
Study 24570980 — intervention group
Group type: COMPARATOR
Intervention: at least 10 mm long implants in augmented bone
Number of subjects: 80
Study 24570980 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 × 5 mm dental implants
Number of subjects: 80
Study 24570980 — intervention group
Group type: COMPARATOR
Intervention: at least 10 mm long implants
Number of subjects: 80
Study 21420888 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 35
Study 21420888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 18155431 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing an endoscopy report to patients after the procedure
Number of subjects: 115
Study 18155431 — intervention group
Group type: COMPARATOR
Intervention: Control group (no report provided)
Number of subjects: 115
Study 16940217 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg, 3 times daily for 16 days
Number of subjects: 22
Study 16940217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 14572169 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (200 mg)
Number of subjects: 136
Study 14572169 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10 mg)
Number of subjects: 136
Study 10982087 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9106924 — intervention group
Group type: EXPERIMENTAL
Intervention: Ialugen cream (hyaluronic acid)
Number of subjects: 134
Study 9106924 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 134
Study 8472981 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine followed by polidocanol
Number of subjects: 75
Study 8472981 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute alcohol
Number of subjects: 75
Study 8472981 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 75
Study 3705659 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenzepine 1 mg
Number of subjects: 9
Study 3705659 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenzepine 2 mg
Number of subjects: 9
Study 3705659 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenzepine 3 mg
Number of subjects: 9
Study 3705659 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenzepine 5 mg
Number of subjects: 9
Study 3705659 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenzepine (all doses)
Number of subjects: 9
Study 30094649 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenograft (Bio‐Oss®)
Number of subjects: 6
Study 30094649 — intervention group
Group type: EXPERIMENTAL
Intervention: Alloplastic tricalcium phosphate (Sil‐Oss®)
Number of subjects: 6
Study 30094649 — intervention group
Group type: COMPARATOR
Intervention: Control (no biomaterial)
Number of subjects: 6
Study 30130346 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraction-associated heart rate deceleration pattern in hypovolemic women (defined by admission pulse pressure <45 mm Hg)
Number of subjects: 388
Study 30130346 — intervention group
Group type: COMPARATOR
Intervention: Contraction-associated heart rate deceleration pattern in euvolemic women (defined by admission pulse pressure ≥50 mm Hg)
Number of subjects: 388
Study 30130346 — intervention group
Group type: EXPERIMENTAL
Intervention: Postepidural FHR abnormalities
Number of subjects: 388
Study 30130346 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic hypotension
Number of subjects: 388
Study 30130346 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for resuscitative interventions
Number of subjects: 388
Study 26620496 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-5108 monotherapy (Panel1) at doses ranging from 200 to 1800 mg, administered p.o. BID Q12h on days 1-2 in 14-21 day cycles.
Number of subjects: 35
Study 26620496 — intervention group
Group type: COMPARATOR
Intervention: MK-5108 in combination with docetaxel (Panel2) at 450 mg/day, administered IV docetaxel 60 mg/m2.
Number of subjects: 35
Study 25416527 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIGGER trial - open-label cluster randomised trial
Number of subjects: 0
Study 25416527 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPPS trial - open-label trial
Number of subjects: 0
Study 22122738 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative fractional laser therapy (10,600-nm FLT, 10 mJ/microbeam, 35-45% coverage) for three to five sessions
Number of subjects: 18
Study 22122738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonablative fractional laser therapy (1,550-nm FLT, 15 mJ/microbeam, 14-20% coverage) for three to five sessions
Number of subjects: 18
Study 22122738 — intervention group
Group type: COMPARATOR
Intervention: Topical bleaching
Number of subjects: 18
Study 19853332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of glutamate
Number of subjects: 69
Study 19853332 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 69
Study 19853332 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (glutamate and saline)
Number of subjects: 69
Study 17653058 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with ketamine
Number of subjects: 37
Study 17653058 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia without ketamine
Number of subjects: 37
Study 17653058 — intervention group
Group type: EXPERIMENTAL
Intervention: Local (peribulbar) anesthesia
Number of subjects: 37
Study 14990914 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 360
Study 14990914 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Number of subjects: 360
Study 14990914 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Number of subjects: 360
Study 14990914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 11075876 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower calcium intake and higher phosphorus intake
Number of subjects: 27062
Study 11075876 — intervention group
Group type: COMPARATOR
Intervention: Calcium and phosphorus intake
Number of subjects: 27062
Study 9353602 — intervention group
Group type: EXPERIMENTAL
Intervention: Three meals per day
Number of subjects: 13
Study 9353602 — intervention group
Group type: COMPARATOR
Intervention: Nine meals per day
Number of subjects: 13
Study 8222514 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-out water immersion
Number of subjects: 8
Study 8222514 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 8
Study 8222514 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients
Number of subjects: 8
Study 8222514 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 8
Study 3898832 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (900 mg before meals and at bedtime)
Number of subjects: 138
Study 3898832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 3898832 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 138
Study 31574879 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) applied for the treatment of infected dentin, followed by restoration with high viscosity glass ionomer cement.
Number of subjects: 0
Study 31574879 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving removal of softened dentin with sharp dentine curettes and restoration with high viscosity glass ionomer cement.
Number of subjects: 0
Study 28005265 — intervention group
Group type: EXPERIMENTAL
Intervention: tabalumab 100 mg
Number of subjects: 220
Study 28005265 — intervention group
Group type: EXPERIMENTAL
Intervention: tabalumab 300 mg
Number of subjects: 220
Study 28005265 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 220
Study 28005265 — intervention group
Group type: EXPERIMENTAL
Intervention: low baseline BAFF expression
Number of subjects: 220
Study 28005265 — intervention group
Group type: EXPERIMENTAL
Intervention: high baseline BAFF expression
Number of subjects: 220
Study 25951308 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorphous calcium phosphate (ACP) containing resin-based sealant (Aegis)
Number of subjects: 75
Study 25951308 — intervention group
Group type: COMPARATOR
Intervention: Fluoride-containing resin-based sealant (Helioseal F)
Number of subjects: 75
Study 25951308 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoride resin-based sealant (Helioseal)
Number of subjects: 75
Study 25951308 — intervention group
Group type: COMPARATOR
Intervention: Helioseal FS
Number of subjects: 75
Study 25951308 — intervention group
Group type: COMPARATOR
Intervention: Aegis FS
Number of subjects: 75
Study 24814500 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of LPS (0.8 ng/kg)
Number of subjects: 0
Study 24814500 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose LPS (0.4 ng/kg)
Number of subjects: 0
Study 24814500 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo control group)
Number of subjects: 0
Study 21080416 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 40
Study 21080416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19378700 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisis Resolution Team (CRT) care
Number of subjects: 0
Study 19378700 — intervention group
Group type: COMPARATOR
Intervention: Standard services
Number of subjects: 0
Study 17582069 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy (0.625 mg per day)
Number of subjects: 1064
Study 17582069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1064
Study 17582069 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 1064
Study 17582069 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy (with at least 80% adherence)
Number of subjects: 1064
Study 15105237 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP (10 cm H(2)O) during induction with 100% oxygen for 5 min and mechanical ventilation via face mask
Number of subjects: 23
Study 15105237 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PEEP or continuous positive airway pressure)
Number of subjects: 23
Study 15105237 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP group
Number of subjects: 23
Study 15105237 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study 10735926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (400 mg b.d.) with amoxycillin (1 g b.d.) and clarithromycin (500 mg b.d.)
Number of subjects: 192
Study 10735926 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (20 mg b.d.) with amoxycillin (1 g b.d.) and clarithromycin (500 mg b.d.)
Number of subjects: 192
Study 9177359 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (200 mg testosterone cypionate biweekly for 12 months)
Number of subjects: 32
Study 9177359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 1539524 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of warfarin (within 48 hours of heparin)
Number of subjects: 119
Study 1539524 — intervention group
Group type: COMPARATOR
Intervention: Late initiation of warfarin (96 hours or later after heparin)
Number of subjects: 119
Study 3873713 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal transection
Number of subjects: 76
Study 3873713 — intervention group
Group type: COMPARATOR
Intervention: Injection sclerotherapy
Number of subjects: 76
Study 30952558 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 0
Study 30952558 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 28795584 — intervention group
Group type: EXPERIMENTAL
Intervention: SMSMessenger application for sending automated text message reminders
Number of subjects: 0
Study 27539884 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptoglobin 2-2 genotype
Number of subjects: 1303
Study 27539884 — intervention group
Group type: COMPARATOR
Intervention: Intensive therapy
Number of subjects: 1303
Study 27539884 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1303
Study 24326799 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Misoprostol
Number of subjects: 0
Study 24326799 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Ergometrine
Number of subjects: 0
Study 24326799 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Oxytocin
Number of subjects: 0
Study 23584366 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release prednisone (MR-pred) 5 mg/day
Number of subjects: 0
Study 23584366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20527506 — intervention group
Group type: EXPERIMENTAL
Intervention: CrossAction Pro‐Health (CAPH)
Number of subjects: 10
Study 20527506 — intervention group
Group type: EXPERIMENTAL
Intervention: CrossAction (CA)
Number of subjects: 10
Study 20527506 — intervention group
Group type: EXPERIMENTAL
Intervention: Exceed (EX)
Number of subjects: 10
Study 20527506 — intervention group
Group type: COMPARATOR
Intervention: Advantage 123 (ADV 123)
Number of subjects: 10
Study 20527506 — intervention group
Group type: COMPARATOR
Intervention: Indicator (IND)
Number of subjects: 10
Study 18833969 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 0
Study 16620136 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 microg/kg
Number of subjects: 50
Study 14669764 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive continuous positive airway pressure ventilation (CPAP) using a new helmet interface
Number of subjects: 22
Study 14669764 — intervention group
Group type: COMPARATOR
Intervention: Standard facial mask for CPAP
Number of subjects: 22
Study 10979160 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment tailored to individual symptoms and standardized component for health and immune function
Number of subjects: 11
Study 10979160 — intervention group
Group type: COMPARATOR
Intervention: Control-needling group with clinically irrelevant acupuncture points
Number of subjects: 11
Study 8971289 — intervention group
Group type: EXPERIMENTAL
Intervention: fedotozine (30 mg t.d.s.)
Number of subjects: 27
Study 8971289 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study 1593505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural problem solving treatment
Number of subjects: 0
Study 1593505 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 30426300 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP (160 mcg/kg/min)
Number of subjects: 33
Study 30426300 — intervention group
Group type: COMPARATOR
Intervention: Adenosine (140 mcg/kg/min)
Number of subjects: 33
Study 28695632 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg)
Number of subjects: 31
Study 26381535 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite index of exercise capacity (EC) and exercise heart rate responses
Number of subjects: 1531
Study 26381535 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise test risk score (calculated as the sum of hazard ratios related to abnormal EC, CRI, and HRR)
Number of subjects: 1531
Study 26381535 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of exercise test risk score to established risk model
Number of subjects: 1531
Study 23922063 — intervention group
Group type: EXPERIMENTAL
Intervention: Care guide intervention
Number of subjects: 2135
Study 23922063 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2135
Study 21071171 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality using Wii gaming technology (VRWii)
Number of subjects: 105
Study 21071171 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard occupational therapy (SOT)
Number of subjects: 105
Study 21071171 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study 19898595 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (20 mg VO e/12h) with Amoxicillin (1g VO e/12h) and Clarithromycin (500 mg VO e/12h)
Number of subjects: 83
Study 19898595 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (20 mg VO e/12h) with Amoxicillin (1g VO e/12h) and Clarithromycin (500 mg VO e/12h)
Number of subjects: 83
Study 17767050 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoplasmapheresis (LPE) in addition to medical treatment
Number of subjects: 66
Study 17767050 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment only (Control)
Number of subjects: 66
Study 15557008 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic gas mixture
Number of subjects: 28
Study 15557008 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic gas mixture
Number of subjects: 28
Study 15557008 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic CO(2) rebreathing
Number of subjects: 28
Study 15557008 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic CO(2) rebreathing
Number of subjects: 28
Study 15557008 — intervention group
Group type: COMPARATOR
Intervention: CO(2) rebreathing
Number of subjects: 28
Study 12101789 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (initial dose of 15 mg intravenously, followed by 100 mg/d orally)
Number of subjects: 35
Study 12101789 — intervention group
Group type: COMPARATOR
Intervention: Control group (no metoprolol administered)
Number of subjects: 35
Study 12101789 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 35
Study 11225795 — intervention group
Group type: EXPERIMENTAL
Intervention: cHUT (conventional nitroglycerin test)
Number of subjects: 84
Study 11225795 — intervention group
Group type: EXPERIMENTAL
Intervention: aHUT (accelerated nitroglycerin test)
Number of subjects: 84
Study 11225795 — intervention group
Group type: EXPERIMENTAL
Intervention: cHUT drug-free phase
Number of subjects: 84
Study 11225795 — intervention group
Group type: EXPERIMENTAL
Intervention: cHUT NTG phase
Number of subjects: 84
Study 11225795 — intervention group
Group type: EXPERIMENTAL
Intervention: aHUT
Number of subjects: 84
Study 7484845 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fish oil
Number of subjects: 0
Study 2080948 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of co-dergocrine mesilate and nifedipine (Pontuc)
Number of subjects: 22
Study 2080948 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 22
Study 469515 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of L‐tryptophan
Number of subjects: 15
Study 469515 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/4 g of L‐tryptophan
Number of subjects: 15
Study 469515 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/2 g of L‐tryptophan
Number of subjects: 15
Study 469515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30791804 — intervention group
Group type: EXPERIMENTAL
Intervention: sifalimumab (IV 1.0, 3.0, and 10.0 mg/kg or subcutaneous 100 mg every 2 weeks; IV 600 and 1200 mg every 6 weeks)
Number of subjects: 51